ANDAORALFOR SUSPENSION
Approved
Nov 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Mechanism of Action
drug. [see Microbiology ]
Indications (13)
the following infections in adultsskin structure infections Urinary tract infections Limitations of Useindicating no beta-lactamase productionAmoxicillinclavulanate potassium for oral suspension should not be useddevelopment of drug-resistant bacteriamaintain the effectiveness of Amoxicillinclavulanate potassium for oral suspensionother antibacterial drugsclavulanate potassium for oral suspension should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteriastrongly suspected to be caused by bacteria